Introduction
Friedenstein and coworkers, in a series of seminal studies in the 1960s and 1970s 1 , showed that the osteogenic potential of bone marrow (BM) cells was associated with a minor subpopulation of the cell of the bone marrow isolate. These cells were distinguishable from the majority of hematopoietic cells by their rapid adherence to tissue culture vessels and by the fibroblast-like appearance of their progeny in culture, pointing to their origin from the stromal compartment of BM. The currently popular, though perhaps inaccurate, term mesenchymal stem cells (MSCs) was first coined in 1991 by Dr. Arnold Caplan 2 . Work by Darwin Prockop and others 3, 4 further defined the cells and their adipogenic, osteogenic, and chondrogenic differentiation potentials in vitro. Cells with similar properties from other tissues ( Figure 1) were reported, such as synovium 5 , umbilical cord blood 6 , placent 7 , adipose tissue 8 , dental pulp 9 , etc. MSC can modulate the activity of immune cells by secreting soluble factors and via cell-cell contact. This property has two potential implications: substitution of autologous MSCs with off-the-shelf allogenic MSC products, and treatment of immune-mediated diseases, like acute graft-versushost-disease (GvHD), Crohn's disease, multiple sclerosis, or other autoimmune diseases.
The multilineage differentiation potentials and immunomodulatory function of MSCs, and their ability to obtain and grow as autologous cells in large quantities has led to the birth of an entire subfield of regenerative medicine. More than a thousand trials have been conducted and more than fifty companies offer commercial MSC products from different sources for treatment of various diseases.
In the field of musculoskeletal diseases, MSCs have been proposed to treat osteoarthritis and inflammatory arthritis. Eighteen clinical trials
Discussion

Chondrogenic capacity of MSCs
Injury to chondral tissue eventually leads to degeneration of joints trials exploring its use in rheumatoid arthritis with its immunomodulatory property.
This review is to summarize preclinical studies of MSC or MSC-like cells in arthritis, with focus on currently unsolved issues in utilising the using MSCs for arthritis treatment are currently registered at clinicaltrial. gov; among them, 16 trials (Table 1) investigate the application of MSCs in osteoarthritis or chondral defects, using its regenerative property, with three trials of allogenic MSCs and two of MSCs on endogenous chondrogenic cells. Pathogenesis of osteoarthritis is far more complicated than cartilage defect; it involves decreased matrix synthesis, increased proteolytic degradation of matrix, and increased chondrocyte apoptosis. Clinically, besides articular cartilage loss, it has features of osteophytes, bone sclerosis, and subchondral cysts. Therefore, preclinical studies of MSC transplantation into osteoarthritis animal models, rather than into animals with chondral defects, are essential to help us predict the results of clinical studies in osteoarthritis. The first study in a large animal model of osteoarthritis was conducted in 2003 in caprine model. Twenty weeks after MSC injection, degeneration of the articular cartilage, osteophytic remodelling, and subchondral sclerosis were reduced in the injected joints compared to control joints 16 .
Immunomodulatory property of MSCs
Understanding the immunomodulatory function of MSCs is pivotal in the application of allogenic MSCs and developing "off-the-shelf" MSC products. However, it is controversial whether these cells can escape immune surveillance of the recipient and achieve long-term engraftment.
It has been well-known for a decade that MSCs can modulate the activity of immune cells and secrete cytokines and chemokines. In vitro studies show that cultured MSCs can suppress T cell proliferation 17 , inhibit maturation of monocytes into dendritic cells and its antigen presentation function 18, 19 , and inhibit respiratory burst in neutrophils 20 . MSCs have very limited expression of MHC class II molecules in cell cultures, and do not express co-stimulatory molecules, including CD40, CD80, or CD86. The immunosuppressive function is likely to be conducted via soluble factors secreted by MSCs, including transforming growth factor-beta (TGF-β), currently being investigated. A number of growth factors and transcriptional factors have been shown to influence chondrogenic differentiation of MSCs. Members of transforming growth factor-beta (TGF-β) superfamily, including TGF-β1, TGF-β3, bone morphogenic protein 2 (BMP-2), BMP-4, BMP-7, and growth differentiation factor-5 (GDF-5), increase proliferation and cartilaginous extracellular matrix production, promote chondrogenic differentiation of MSCs, and/or decrease type I collagen gene expression; insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF-2), and FGF-18 have been shown to have similar effects 12 . Overexpression of Sox9, alone 13 , or in combination with Sox5 and Sox6
14
, has been shown to enhance chondrogenesis. A phase I clinical trial using genetically modified chondrocytes expressing TGF-β1 has been carried out and completed; recently, it has been advanced to a phase II study in the U. S. and a phase IIb study in Korea. However, genetically modified chondroprogenitor cells, including mesenchymal stem cells, have not been studied extensively in animal models or used in any clinical studies.
Long-term survival and integration of MSCs have not been thoroughly evaluated in animal models. In a study of direct intra-articular injection of human bone marrow stromal cells mixed with hyaluronic acid into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis, partial cartilage repair was observed after five weeks; migration and differentiation into chondrocytes was demonstrated using carboxyfluorescein diacetate succinimidyl ester (CFSE) labelled cells 15 . In this study, expression of type II collagen was observed not only in the injected MSCs, but also in the residual layer of chondrocytes as well. This observation raised the question whether the cartilage was regenerated from the injected MSCs or the paracrine effect and osteoarthritis. As cartilage is a tissue with very poor self-regeneration ability, transplantation of The second question is how to translate in vitro chondrogenic capacity into in vivo cartilage repair function. In a rabbit model of cartilage defect, synovium-derived MSC and bone marrow stromal cells demonstrated superior chondrogenic capacity on histology, both in vivo and in vitro, when compared to adiposederived stem cells and muscle-derived stem cells 11 . The consistency of in vitro and in vivo results is encouraging; however, limited conclusions can be drawn due to lack of quantitative measurement.
To promote chondrogenic capacity, genetically modified MSCs are 
Conclusion
Chondrogenic differentiation property and immunomodulatory function of MSCs can be potentially used to treat arthritis, including osteoarthritis and inflammatory arthritis. A better understanding of the biology of MSCs at cellular level and through preclinical animal models will facilitate application of "off-theshelf" MSCs products in a real clinical setting. Numerous issues remain in utilising the regenerative and immunomodulatory properties of mesenchymal stem cells in treating human diseases. For its application in osteoarthritis, quantitative measurement of in vitro chondrogenic capacity of MSCs and its correlation with in vivo cartilage repair is one of the essential steps. Long-term survival and engraftment have not been demonstrated; various delivery while in the control group using human umbilical vein endothelial cells (HUVEC), the suppressive effect was not observed (unpublished result). This finding is consistent with the in vivo study in the collagen induced arthritis model 28 , which showed that the intravenous injection of fibroblasts efficiently suppressed the clinical signs of arthritis and delayed disease onset, similar to intravenous injection of MSCs. Stromal cells isolated from lymph nodes were also shown to suppress T cell activation and proliferation, partially via NO 29 .
These evidences challenge the notion that the immunomodulatory function is a unique property of MSCs; instead, it may be a common property shared by stromal cells originated from various peripheral tissues.
Clinical trials or case series of MSC in arthritis
The first study of MSC treatment in OA was published in 2002. Twelve patients received transplantation of culture expended, autologous BMSC embedded in collagen gel, into the articular cartilage defect in the medial femoral condyle. Compared with twelve control patients who received cell-free products, at 46 weeks, the study group demonstrated a better arthroscopic and histological grading score, without a significant clinical improvement 30 . A follow-up case report from the same authors reported MRI and histology aspects of transplanted tissue in patients who had significant improvement of clinical symptoms. The authors found that defects were repaired with fibrocartilage, and MRI of the defect area showed decreased intensity with irregularity compared to normal cartilage 31, 32 . Safety data of mesenchymal stem cell transplantation is scarce; in one study of 41 patients who received autologous BMSC transplantation, no tumours or infections were observed between 5 to 137 months of followup, with a mean of 75 months
33
. Unfortunately, outcome measurements hepatocyte growth factor (HGF), nitric oxide (NO), and indolamine dioxygenase (IDO)
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; and cell-cell contact also seems involved 22 . In mixed lymphocyte reaction experiment, an inhibitory effect on effecter T cell proliferation was observed when T cells were co-cultured with allogenic or even xenogenic MSCs
23
. In hematopoietic stem cell transplant (HSCT) recipients who received MSC infusions for treatment of acute GVHD, it was found that immune unresponsiveness was restricted to MSCs and HSCT recipients maintained an allogenic response to allostimuli from MSC donors 24 .
Although these evidences demonstrate that MSCs have immune privilege, recent studies indicate that immune function of MSCs is more complicated than previously described. At low level of interferongamma (IFN-γ), MSCs was found to express MHC class II molecules and have antigen presenting property 25 ; at high level of IFN-γ, MHC class II molecules are down regulated and the expression of programmed cell death 1 ligand (PD-L1), an inhibitory co-stimulatory molecule, is observed 22, 26 . MSCs express toll-like receptors (TLRs), including TLR-3 and TLR-4, and stimulation of TLR-3 leads to the expression of immunosuppressive factors in MSCs while stimulation of TLR-4 induces pro-inflammatory mediators 27 . This finding indicated that the cellular environment of the recipient will affect the balance between pro-inflammatory and anti-inflammatory properties of MSC, and may further influence its engraftment and/or differentiation capacity.
Whether the immunomodulatory function is unique to MSCs remains an intriguing question. In a mixed lymphocyte reaction (MLR) assay, when cocultured with TCRβ+ CD44-CD62L high CD25-Foxp3-naïve T cells, the skin fibroblast (FB) demonstrated similar suppressive effects as adipose-derived stem cells (ADSC), methods have not been compared. Understanding the mechanism of immunomodulatory function of MSCs is pivotal in the application of allogenic MSCs in transplant and its application in treating inflammatory arthritis. Genetic modification that allows MSCs to express chondrogenic factors and anti-inflammatory molecules in a safe way will enhance this process. Risk of cellular therapy will require special consideration when designing a clinical trial. In the long run, safety, effectiveness, and cost will determine its utility in treating arthritis.
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